Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/124277
Title: | Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG) |
Author: | Kovacs, Gabor G. Xie, Sharon X. Lee, Edward B. Robinson, John L. Caswell, Carrie Irwin, David J. Toledo, Jon B. Johnson, Victoria Smith, Douglas H. Alafuzoff, Irina Attems, Johannes Bencze, Janos Bieniek, Kevin F. Bigio, Eileen H. Bodi, Istvan Budka, Herbert Dickson, Dennis W. Dugger, Brittany N. Duyckaerts, Charles Ferrer, Isidro (Ferrer Abizanda) Forrest, Shelley L. Gelpi, Ellen Gentleman, Stephen M. Giaccone, Giorgio Grinberg, Lea T. Halliday, Glenda M. Hatanpaa, Kimmo J. Hof, Patrick R. Hofer, Monika Hortobágyi, Tibor Ironside, James W. King, Andrew Kofler, Julia Kövari, Enikö Kril, Jillian J. Love, Seth Mackenzie, Ian R. Mao, Qinwen Matej, Radoslav McLean, Catriona Muñoz, David G. Murray, Melissa E. Neltner, Janna Nelson, Peter T. Ritchie, Diane Rodriguez, Roberta D. Rohan, Zdenek Rozemüller, Annemieke Sakai, Kenji Schultz, Christian Seilhean, Danielle Smith, Vanessa Tacik, Pawel Takahashi, Hitoshi Takao, Masaki Thal, Dietmar Rudolf Weis, Serge Wharton, Stephen B. White III, Charles L. Woulfe, John M. Yamada, Masahito Trojanowski, John Q. |
Keywords: | Malalties del sistema nerviós Envelliment Nervous system Diseases Aging |
Issue Date: | 1-Jul-2017 |
Publisher: | Oxford University Press |
Abstract: | Aging-related tau astrogliopathy (ARTAG) is a recently introduced terminology. To facilitate the consistent identification of ARTAG and to distinguish it from astroglial tau pathologies observed in the primary frontotemporal lobar degeneration tauopathies we evaluated how consistently neuropathologists recognize (1) different astroglial tau immunoreactivities, including those of ARTAG and those associated with primary tauopathies (Study 1); (2) ARTAG types (Study 2A); and (3) ARTAG severity (Study 2B). Microphotographs and scanned sections immunostained for phosphorylated tau (AT8) were made available for download and preview. Percentage of agreement and kappa values with 95% confidence interval (CI) were calculated for each evaluation. The overall agreement for Study 1 was > 60% with a kappa value of 0.55 (95% CI 0.433-0.645). Moderate agreement (> 90%, kappa 0.48, 95% CI 0.457-0.900) was reached in Study 2A for the identification of ARTAG pathology for each ARTAG subtype (kappa 0.37-0.72), whereas fair agreement (kappa 0.40, 95% CI 0.341-0.445) was reached for the evaluation of ARTAG severity. The overall assessment of ARTAG showed moderate agreement (kappa 0.60, 95% CI 0.534-0.653) among raters. Our study supports the application of the current harmonized evaluation strategy for ARTAG with a slight modification of the evaluation of its severity. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1093/jnen/nlx041 |
It is part of: | Journal of Neuropathology and Experimental Neurology, 2017, vol. 76, num. 7, p. 605-619 |
URI: | http://hdl.handle.net/2445/124277 |
Related resource: | https://doi.org/10.1093/jnen/nlx041 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
KovacsGG.pdf | 233.93 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.